Iguratimod

Iguratimod is an anti-inflammatory small molecule drug used for the treatment of rheumatoid arthritis, together with methotrexate in Japan and China.^[1] As of 2015 the biological target was not known, but it prevents NF-κB activation and subsequently selectively inhibits COX-2 and several inflammatory cytokines.^[1]

Iguratimod

Clinical data
Trade names	Careram; Kolbet
Other names	T-614
ATC code	None
Identifiers
IUPAC name N-(3-Formamido-4-oxo-6-phenoxy-4H-chromen-7-yl)methanesulfonamide
CAS Number	123663-49-0
PubChem CID	124246
ChemSpider	110694
UNII	4IHY34Y2NV
ChEMBL	ChEMBL2107455
CompTox Dashboard (EPA)	DTXSID0048971
ECHA InfoCard	100.236.037
Chemical and physical data
Formula	C17H14N2O6S
Molar mass	374.37 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=S(=O)(Nc3c(Oc1ccccc1)cc2c(O/C=C(\C2=O)NC=O)c3)C
InChI InChI=1S/C17H14N2O6S/c1-26(22,23)19-13-8-15-12(17(21)14(9-24-15)18-10-20)7-16(13)25-11-5-3-2-4-6-11/h2-10,19H,1H3,(H,18,20) Key:ANMATWQYLIFGOK-UHFFFAOYSA-N

Adverse effects include elevated transaminases, nausea, vomiting, stomach pain; rashes, and itchiness.^[1]

It is a derivative of 7-methanesulfonylamino-6-phenoxychromones and is a chromone with two amide groups; it was first published in 2000.^[1][2] It was submitted for regulatory approval in Japan in 2003; the application was withdrawn in 2009, and it was resubmitted with additional data in 2011 and approved for marketing in Japan in 2012.^[1] Eisai and Toyama Chemical market it in Japan.^[3] Approval was obtained in China in 2011 by Simcere, independently of the Japanese originators.^[1][4]

During discovery and development it was called T-614 and it is marketed under the names Careram and Kolbet.^[5]